Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349036 | 1.00 | GRIA2 (0.41) | GRIA2PKMNR1H2NR1H3ALDH1A1 | |
| SCHEMBL1348629 | 0.91 | GRIA2 (0.35) | GRIA2PKMNR1H2NR1H3ALDH1A1 | |
| SCHEMBL1348963 | 0.91 | PKM (0.39) | PKMALDH1A1RAB9AKMT2ADPP4 | |
| SCHEMBL1349099 | 0.90 | GRIA2 (0.43) | GRIA2NR1H2NR1H3DRD2RXRA | |
| SCHEMBL1347803 | 0.88 | GRIA2 (0.44) | GRIA2NR1H2NR1H3DRD2RXRA | |
| SCHEMBL1348579 | 0.88 | GRIA2 (0.38) | GRIA2NR1H2NR1H3RXRADPP4 | |
| SCHEMBL1348838 | 0.87 | GRIA2 (0.41) | GRIA2NR1H2NR1H3DRD2RXRA | |
| SCHEMBL1348861 | 0.86 | PARG (0.41) | GRIA2PKMALDH1A1RAB9AKMT2A | |
| SCHEMBL1348324 | 0.85 | NR1H2 (0.42) | PKMNR1H2NR1H3RXRA | |
| SCHEMBL1349116 | 0.85 | ALDH1A1 (0.44) | ALDH1A1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | claimed |
| US-8063088-B2 | Imidazolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | claimed |
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8063088-B2 | Imidazolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | NR1H2, NR1H3, NR1D2 | GRIA2 858/4885PKM 1863/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.